NU-CEFUROXIME TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

CEFUROXIME (CEFUROXIME AXETIL)

可用日期:

NU-PHARM INC

ATC代码:

J01DC02

INN（国际名称）:

CEFUROXIME

剂量:

250MG

药物剂型:

TABLET

组成:

CEFUROXIME (CEFUROXIME AXETIL) 250MG

给药途径:

ORAL

每包单位数:

60/100/250

处方类型:

Prescription

治疗领域:

SECOND GENERATION CEPHALOSPORINS

產品總結:

Active ingredient group (AIG) number: 0122448001; AHFS:

授权状态:

CANCELLED (UNRETURNED ANNUAL)

授权日期:

2018-03-28

产品特点

Page 1 of 26
PRODUCT MONOGRAPH
PR
NU-CEFUROXIME
CEFUROXIME AXETIL TABLETS
250 MG AND 500 MG CEFUROXIME/TABLET
NU-PHARM STANDARD
ANTIBIOTIC
NU-PHARM INC.
DATE OF PREPARATION:
50 MURAL ST., UNITS 1 & 2
OCTOBER 20, 2009
RICHMOND HILL, ONTARIO
L4B 1E4
CONTROL#: 133377
Page 2 of 26
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................................3
SUMMARY PRODUCT
INFORMATION.................................................................................3
INDICATIONS AND CLINICAL
USE.......................................................................................3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND
PRECAUTIONS.........................................................................................4
ADVERSE REACTIONS
.........................................................................................................5
DRUG
INTERACTIONS..........................................................................................................6
DOSAGE AND
ADMINISTRATION.........................................................................................6
OVERDOSAGE.......................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................7
STORAGE AND STABILITY
...................................................................................................7
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................7
PART II: SCIENTIFIC
INFORMATION.......................................................................................9
PHARMACEUTICAL
INFORMATION.....................................................................................9
CLINICAL
TRIALS.......................................................................................................